Results 41 to 50 of about 3,955 (172)

Cytokine-induced killer (CIK) cell therapy for patients with hepatocellular carcinoma: efficacy and safety

open access: yesExperimental Hematology & Oncology, 2012
Purpose To evaluate the efficacy of cytokine-induced killer (CIK) cell therapy in the treatment of hepatocellular carcinoma. Materials and methods Randomized phase II and III trials on CIK cell-based therapy were identified by electronic searches using a
Ma Yue   +5 more
doaj   +1 more source

Growth of Human Colorectal Cancer SW1116 Cells Is Inhibited by Cytokine-Induced Killer Cells

open access: yesClinical and Developmental Immunology, 2011
Previous reports have suggested that treatment with cytokine-induced killer (CIK) cells may benefit patients with various types of tumor. The aim of this study was to evaluate the antitumor effects of CIK cells against the colorectal cancer line SW1116 ...
Yao Wang   +6 more
doaj   +1 more source

The Efficacy of CIK-Based Immunotherapies for Advanced Solid Tumors [PDF]

open access: yesTechnology in Cancer Research & Treatment, 2016
Objective: To investigate the efficacy of cytokine-induced killer cell-based immunotherapies in patients with advanced malignant solid tumors and the difference in clinical efficiency among 3 kinds of cytokine-induced killer cell-based immunotherapies ...
Hongjin, Chu   +7 more
openaire   +2 more sources

PD-L1 expression is a predictive biomarker for CIK cell-based immunotherapy in postoperative patients with breast cancer

open access: yesJournal for ImmunoTherapy of Cancer, 2019
Background A sequential combination of radiochemotherapy/endocrinotherapy and cytokine-induced killer cell (CIK) infusion has been shown to be an effective therapy for post-mastectomy breast cancer based on statistical analysis of the patient population.
Zi-Qi Zhou   +8 more
doaj   +1 more source

Combined therapy with cytokine-induced killer cells and oncolytic adenovirus expressing IL-12 induce enhanced antitumor activity in liver tumor model. [PDF]

open access: yesPLoS ONE, 2012
Both adoptive immunotherapy and gene therapy hold a great promise for treatment of malignancies. However, these strategies exhibit limited anti-tumor activity, when they are used alone.
Zhi Yang   +12 more
doaj   +1 more source

Role of the adaptor protein CIKS in the activation of the IKK complex [PDF]

open access: yesBiochemical and Biophysical Research Communications, 2003
Nuclear factor kappaB (NF-kappaB) plays a pivotal role in numerous cellular processes, including stress response, inflammation, and protection from apoptosis. Therefore, the activity of NF-kappaB needs to be tightly regulated. We have previously identified a novel gene, named CIKS (connection to IkappaB-kinase and SAPK), able to bind the regulatory sub-
MAURO C   +6 more
openaire   +6 more sources

Combining antiangiogenic therapy with adoptive cell immunotherapy exerts better antitumor effects in non-small cell lung cancer models. [PDF]

open access: yesPLoS ONE, 2013
INTRODUCTION: Cytokine-induced killer cells (CIK cells) are a heterogeneous subset of ex-vivo expanded T lymphocytes which are characterized with a MHC-unrestricted tumor-killing activity and a mixed T-NK phenotype.
Shujing Shi   +5 more
doaj   +1 more source

CIKS/Act1-Mediated Signaling by IL-17 Cytokines in Context: Implications for How a CIKS Gene Variant May Predispose to Psoriasis [PDF]

open access: yesThe Journal of Immunology, 2012
Abstract Psoriasis is a relapsing skin disease characterized by abnormal keratinocyte proliferation and differentiation and by an influx of inflammatory immune cells. Recently, IL-17 cytokines have been strongly implicated as critical for the pathogenesis of this disease.
Søren Ulrik, Sønder   +4 more
openaire   +2 more sources

Effect of dendritic cell-cytokine-induced killer cells in patients with advanced colorectal cancer combined with first-line treatment

open access: yesWorld Journal of Surgical Oncology, 2017
Background Surgical resection combined with adjuvant chemotherapy is considered as the gold-standard treatment for advanced colorectal cancer patients. These patients have a poor 5-year survival rate of 5% or less.
Yunqing Xie   +5 more
doaj   +1 more source

CEO Managerial Ability and the Strategic Repetition of Climate Disclosures

open access: yesBusiness Strategy and the Environment, EarlyView.
ABSTRACT This study examines whether CEO managerial ability shapes the repetition of firms' climate‐related disclosures in mandatory 10‐K filings. Climate reporting is highly judgment based and central to firms' broader climate‐risk management strategies, yet little is known about why some firms repeatedly use similar climate narratives and others ...
Javad Rajabalizadeh
wiley   +1 more source

Home - About - Disclaimer - Privacy